Picture EBD Group BioPharm America 2019 Boston September 600x60px
Organisation › Details

Loxo Oncology Inc. (Nasdaq: LOXO)

Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. *


Period Start 2017-07-31 existent
Products Industry larotrectinib (LOXO-101)
  Industry 2 BAY 2731954 (LOXO-195)
Person Person Bilenker, Josh (Loxo Oncology 201811 CEO)
  Street 281 Tresser Blvd.
  City 06901 Stamford, CT
  Tel +1-203-653-3880
    Address record changed: 2017-11-22
    * Document for �About Section�: Loxo Oncology, Inc.. (11/14/17). "Press Release: Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195". Stamford, CT.
Record changed: 2019-02-18


Picture [LSUS] – The Business Web Portal 650x112px

More documents for Loxo Oncology Inc. (Nasdaq: LOXO)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

» top